

Hester Biosciences Limited Head Office Pushpak, 1st Floor

Panchvati Circle Motilal Hirabhai Road Ahmedabad 380006 Gujarat, India

Phone +9179 26445106

Plant Address Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +9179 26445105

Email mail@hester.in Toll Free 1800 233 7937 www.hester.in

CIN L99999GJ1987PLC022333

#### STATEMENT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON MARCH 31, 2021

	Amount in INR N					
Sr.	Particulars		Quarter Ended		Year E	nded
No.		31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020
		Audited (Refer note 7)	Unaudited	Audited (Refer note 7)	Audited	Audited
	Income					
1	Revenue from Operations	631.58	528.18	414.32	2,084.77	1,694.25
2	Other Income	1.20	6.35	2.97	16.48	29.27
3	Total Income	632.78	534.53	417.29	2,101.25	1,723.52
4	Expenses					
	(a) Cost of material consumed	91.32	53.49	54.01	241.75	276.23
	(b) Purchases of stock-in-trade	80.31	84.22	46.05	252.09	171.89
	(c) Change in inventories of finished goods, traded goods and work in progress	27.50	(34.24)	(49.76)	40.14	(155.74)
	(d) Employee benefits expense	97.87	86.38	109.39	334.51	371.56
	(e) Finance cost	4.72	9.38	17.75	39.47	50.34
	(f) Depreciation and amortisation expense	24.46	24.36	22.86	96.33	93.85
	(g) Other expenses	128.43	132.49	151.98	496.35	503.10
	Total Expenses	454.61	356.08	352.27	1,500.64	1,311.23
5	Profit Before Tax and Exceptional Items	178.17	178.45	65.01	600.61	412.29
6	Exceptional Items (Refer Note 2)	(52.78)	-	-	(52.78)	-
7	Profit before tax	125.40	178.45	65.01	547.83	412.29
8	Tax Expense					
	Current tax	49.78	46.57	20.02	163.65	118.05
	Deffered tax	(12.97)	(1.03)	(5.04)	(14.83)	(18.00)
	Total Tax Expense	36.81	45.54	14.98	148.82	100.05
9	Profit After Tax	88.59	132.91	50.03	399.01	312.24
10	Other Comprehensive Income					
	Items that will not be reclassified to Profit or Loss					
	Remesurement Gain/(Loss) on Defined Benefit Plans	0.01	0.95	0.46	2.86	(5.36)
	Income Tax Impact	(0.00)	(0.24)	(0.12)	(0.72)	1.35
	Total Other Comprehensive Income	0.01	0.71	0.35	2.14	(4.01)
11	Total Comprehensive Income for the period	88.60	133.62	50.37	401.15	308.23
12	Paid-up equity share capital				85.07	85.07
13	Other Equity				2,290.74	1,945.73
14	Earnings Per Share (Face Value of INR 10 each) (Not Annualised) - Basic & Diluted (INR)	10.41	15.62	5.88	46.90	36.70



**Total Equity and Liabilities** 

Hester Biosciences Limited Head Office Pushpak, 1st Floor Panchvati Circle Motilal Hirabhai Road Ahmedabad 380006

Gujarat, India Phone +9179 26445106

Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +9179 26445105

2,820.15

2,771.90

Email mail@hester.in Toll Free 1800 233 7937

www.hester.in

CIN L99999GJ1987PLC022333

STATEMENT OF AUDITED STANDALONE ASSETS AND LIABILITES AS AT 31 MARCH 2021 Amount in INR Million As at As at **Particulars** 31-03-2020 31-03-2021 I. ASSETS (1) Non-current assets 863.07 960.81 (a) Property Plant & Equipment 35.38 8.74 (b) Capital Work-in-Progress (c) Other Intangible Assets 3.30 3.93 0.56 2.90 (d) Biological Assets other than the Bearer Plants (e) Financial Assets 438.85 406.71 Investments (i) 7.40 50.86 (ii) Loans 41.14 52.37 (iii) Other Finacial Assets 34.39 53.77 (f) Other Non-current Assets 1,424.09 1,540.09 (2) Current assets 570.12 604.32 (a) Inventories (b) Financial Assets (i) Trade Receivables 455.50 447.61 (ii) Cash and Cash Equivalents 12.44 51.90 (iii) Other Financial Assets 4.17 3.99 (iv) Loans 179.99 0.97 173.84 123.02 (c) Other Current Assets 1,396.06 1,231.81 2,820.15 2,771.90 **Total Assets** II. EQUITY AND LIABILITIES (1) Equity (a) Share capital 85.07 85.07 (b) Other equity 2,290.74 1,945.73 2,375.81 2,030.80 (2) Liabilities (a) Non-current liabilities (i) Financial Liabilities -Borrowinas 26.76 74.45 -Other Financial Liabilities 3.03 1.53 (ii) Deferred Tax Liabilities (Net) 68.06 82.89 97.85 158.87 (b) Current liabilities (i) Financial Liabilities 17.10 -Borrowings 318.01 -Trade Payables -Total outstanding dues of micro enterprises and small enterprises 2.98 7.08 -Total outstanding dues of creditors other than micro enterprises and small enterprises 137.27 129.00 -Other Financial Liabilities 124.22 98.35 (ii) Other Current Liabilities 26.83 25.38 (iii) Current Tax Liabilities 29.42 (iv) Provisions 8.67 4.41 346.49 582.23 **Total Liabilities** 444.34 741.10



Phone +9179 26445106

Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +91 79 26445105

 Plant Address
 Email
 mail@hester.in

 Village Merda-Ardraj
 Toll Free
 1 800 233 7937

 Taluka Kadi
 www.hester.in

CIN L99999GJ1987PLC022333

STATEMENT OF AUDITED STANDALONE CASH FLOWS FOR THE YEAR ENDED ON 31 MARCH 2021

Amount in INR Mil					
	Year Ended				
Particulars Particulars	31-03-2021	31-03-2020			
	Audited	Audited			
A. Cash Flow from Operating Activities					
Profit Before Tax	547.83	412.29			
Adjustments For:					
Depreciation and Amortisation Expense	96.33	93.85			
Exceptional Items	52.78	-			
Provision for doubtful debt	2.87	-			
Bad Debts Written off	6.90	0.62			
(Profit) / Loss on Sale of Property, Plant & Equipments	2.69	(4.74)			
Interest expense	37.15	38.18			
Interest Income	(12.94)	(5.40)			
Operating Profit Before Changes in Working Capital	733.61	534.80			
Adjustments For:					
Trade Receivables	(17.65)	(121.52)			
Inventories	34.20	(119.36)			
Other Assets	(50.77)	17.14			
Trade Payables	4.17	55.59			
Other Current Liabilities	2.94	15.28			
Short-term Provisions	4.25	1.19			
Loans	(179.03)	1.61			
Other Financial Liability	0.44	0.57			
Other Financial Assets	3.44	(13.55)			
Cash Generated From Operations	535.60	371.74			
Income Tax paid (net)	(134.89)	(113.52)			
Net Cash Flow from Operating Activities (A)	400.71	258.22			
B. Cash Flow from Investing Activities					
Capital Expenditure on Property, Plant & Equipment	(42.50)	(84.00)			
Proceeds from sale of Property, Plant & Equipment	0.42	9.81			
Investment in Subsidiary Companies	(8.25)	(124.52)			
Proceeds from loans repaid	-	3.82			
Interest received	12.67	4.43			
Investment in Bank Deposits (net)	10.74	(22.87)			
Net Cash Flow used in Investing Activities (B)	(26.92)	(213.32)			
C. Cash Flow from Financing Activities					
Repayment of long term borrowings	(19.04)	(12.60)			
Proceeds/(Repayment) of Short-term Borrowings (net)	(300.91)	108.64			
Interest Paid	(37.15)	(38.18)			
Dividend Paid (Including Dividend Distribution Tax)	(56.15)	(71.79)			
Net Cash Flow used in Financing Activities (C)	(413.25)	(13.92)			
Net Increase / (Decrease) in Cash and Cash Equivalents (A+B+C)	(39.46)	30.98			
Cash and Cash Equivalents at the beginning of the year	51.90	20.92			
Cash and Cash Equivalents at the end of the year	12.44	51.90			



Phone +9179 26445106

Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +9179 26445105

Email mail@hester.in Toll Free 1800 233 7937

www.hester.in

CIN L99999GJ1987PLC022333

#### Notes:

1. The above standalone financial results of Hester Biosciences Limited (the "Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 8 June 2021.

2. Exceptional items includes:

Particulars	Amount (INR in million)
Loss on disposal of Patan Farm	33.21
Impairment of interest accrued / loan to subsidiary	19.57
Total	52.78

3. Followings are the details of segment wise revenue, results, segment assets and liabilities:

(Amount in INR Million)

Double		Quarter Ended	<u> </u>	Year Ended		
Particulars	31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020	
Segment Revenue						
a. Poultry Healthcare	485.49	414.53	313.31	1,558.58	1,269.38	
b. Animal Healthcare	146.09	113.65	101.02	526.19	424.87	
Total	631.58	528.18	414.32	2,084.77	1,694.25	
Segment Results						
a. Poultry Healthcare	120.54	140.04	29.54	388.39	310.61	
b. Animal Healthcare	27.84	41.45	50.26	201.89	122.75	
Total	148.38	181.49	79.80	590.28	433.36	
Finance Costs	4.72	9.38	17.75	39.47	50.34	
Other unallocated expenditure/ (income) (net)	18.26	(6.35)	(2.96)	2.98	(29.27)	
Profit before Tax	125.40	178.45	65.01	547.83	412.29	
Segment Assets						
a. Poultry Healthcare	1,822.52	1,758.82	2,009.42	1,822.52	2,009.42	
b. Animal Healthcare	325.89	287.29	247.17	325.89	247.17	
Unallocated Assets	671.73	819.21	515.33	671.73	515.33	
Total	2,820.15	2,865.32	2,771.91	2,820.15	2,771.91	
Segment Liabilities						
a. Poultry Healthcare	143.64	278.89	132.31	143.64	132.31	
b. Animal Healthcare	39.59	42.98	42.49	39.59	42.49	
Unallocated Liabilities	261.10	256.25	566.31	261.10	566.31	
Total	444.34	578.11	741.11	444.34	741.11	

- 4. During the quarter, the Company has made investment aggregating to INR 23.90 million in the equity shares of its subsidiary, Hester Biosciences Nepal Private Limited.
- 5. The Board of Directors has recommended a dividend of INR 10 per equity share (100%) for FY21, subject to the approval of the shareholders in the ensuing Annual General Meeting.



**Place: Ahmedabad** 

Date: 08.06.2021

Hester Biosciences Limited Head Office Pushpak, 1st Floor Panchvati Circle Motilal Hirabhai Road Ahmedabad 380006 Gujarat, India

Phone +9179 26445106

Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +9179 26445105 Email mail@hester.in Toll Free 1800 233 7937 www.hester.in

CIN L99999GJ1987PLC022333

6. The Code on Social Security, 2020 ("Code") relating to employees benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/ interpretation have not yet been issued. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.

- 7. The figures for the last quarters are the balancing figures between the audited figures in respect of the full year ending 31 March 2021 and 31 March 2020 and the unaudited published year-to-date figures up to 31 December 2020 and 31 December 2019 respectively, being the date of the end of the third guarter of the respective financial years which were subjected to limited review.
- 8. The figures for the previous year/periods have been regrouped/reclassified wherever necessary to make them comparable to current year/period.

For and on behalf of the Board of Directors

Rajiv Gandhi

**CEO & Managing Director** 

DIN: 00438037



Hester Biosciences Limited Head Office Pushpak, 1st Floor Panchvati Circle Motilal Hirabhai Road

Gujarat, India Phone +9179 26445106

Ahmedabad 380006

Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +9179 26445105 Email mail@hester.in Toll Free 1800 233 7937

www.hester.in

CIN L99999GJ1987PLC022333

#### AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31 MARCH 2021

				Amount in INR Mi  Year Ended			
Sr. No.	Particulars	24 02 2024	Quarter Ended	24 02 2020			
NO.		31-03-2021	31-12-2020	31-03-2020	31-03-2021	31-03-2020	
		Audited (Refer note 6)	Unaudited	Audited (Refer note 6)	Audited	Audited	
	Income						
1	Revenue from Operations	641.75	568.94	436.20	2,143.32	1,832.68	
2	Other Income	24.76	12.71	47.92	46.84	63.66	
3	Total Income	666.51	581.66	484.12	2,190.16	1,896.35	
4	Expenses						
	(a) Cost of Materials Consumed	142.47	136.99	62.19	386.59	376.33	
	(b) Purchase of Stock-in-Trade	22.39	28.14	22.34	79.67	65.16	
	(c) Change in inventories of finished goods,	11.69	(28.36)	(55.98)	35.97	(161.68)	
	traded goods and work in progress		` '	` ′		` ′	
	(d) Employee Benefit Expense	111.45	107.91	124.13	389.23	406.51	
	(e) Finance Cost	14.35	15.23	25.42	66.04	73.70	
	(f) Depreciation and Amortisation Expense	36.30	32.66	31.98	133.14	130.72	
	(g) Other Expenses	155.98	112.49	211.64	565.29	592.32	
_	Total Expenses	494.63	405.06	421.71	1,655.92	1,483.09	
	Profit Before Tax and Exceptional Items	171.87	176.60	62.41	534.24	413.26	
6	Exceptional Items (Refer Note 2)	(33.21)	-	-	(33.21)	-	
l _	Profit before tax	138.66	176.60	62.41	501.03	413.26	
7	Tax Expense						
	Current tax	51.86	48.35	20.27	169.47	121.67	
	Deferred tax	(14.17)	(0.44)	(5.47)	(15.42)	(18.43)	
	Total Tax Expense	37.69	47.91	14.81	154.05	103.24	
	Profit After Tax	100.97	128.69	47.60	346.98	310.02	
	Other Comprehensive Income						
	Items that will not be reclassified to Profit						
	or Loss Remesurement Gain/(Loss) on Defined Benefit Plans						
	Control of the cont	0.01	0.95	0.46	2.86	(5.36)	
	Income Tax Impact	(0.00)	(0.24)	(0.12)	(0.72)	1.35	
	Items that will be reclassified to Profit or	· ´	,	,	,		
	Loss						
	Foreign Currency Translation Reserve	(17.59)	(18.18)	20.63	(17.94)	24.49	
	Income Tax Impact	-	-	-	-	-	
	Total Other Comprehensive Income	(17.58)	(17.47)	20.97	(15.80)	20.48	
	Total Comprehensive Income for the period	83.39	111.21	68.57	331.18	330.50	
11	Profit for the period attributable to:						
	(i) Owners of the Company	96.89	123.45	27.41	344.30	291.71	
	(ii) Non Controlling Interest	4.08	5.24	20.20	2.68	18.32	
	Other Comprehensive Income for the peiod						
	attributable to:	(2.50)	(10.54)	20.07	(45.00)	20.40	
	(i) Owners of the Company	(3.50)	(18.54)	20.97	(15.80)	20.48	
4.0	(ii) Non Controlling Interest	(14.08)	1.07	-	-	-	
13	Total Comprehensive Income for the peiod attributable to:						
	(i) Owners of the Company	93.39	104.91	48.38	328.50	312.19	
	(ii) Non Controlling Interest	(10.00)	6.30	20.20	2.68	18.32	
1							
	Paid-up equity share capital (face value of INR 10)				85.07	85.07	
	Reserve as shown in the Audited Balance Sheet of				2,198.01	1,925.65	
	the previous year				, 55552	,=====	
10	Earnings Per Share (Face Value of INR 10 each)	11.87	15.13	5.60	40.79	36.44	
<u></u>	(Not Annualised) - Basic & Diluted (INR)						



Hester Biosciences Limited Head Office

Pushpak, 1st Floor Panchvati Circle Motilal Hirabhai Road Ahmedabad 380006

Gujarat, India Phone +9179 26445106 Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +9179 26445105 Email mail@hester.in
Toll Free 1800 233 7937

www.hester.in

CIN L99999GJ1987PLC022333

STATEMENT OF AUDITED CONSOLIDATED ASSETS A	ND LIABILITES AS	AT 31 MARCH
		nount in INR Million
Particulars	As at 31-03-2021	As at 31-03-2020
I. ASSETS		0_ 00 _0_0
(1) Non-current assets		
(a) Property, Plant & Equipment	1,322.87	1,418.54
(b) Capital Work-in-Progress	1,089.87	741.51
(c) Other Intangible Assets	4.21	3.93
(d) Biological Assets other than the Bearer Plants	0.56	2.90
(e) Financial Assets		
(i) Investments	-	-
(ii) Loans	41.14	- 
(e) Financial Assets	41.14	52.37
(f) Other Non-current Assets	36.78	53.68
(2) Current posets	2,495.44	2,272.93
(2) Current assets	622,22	639.67
(a) Inventories	022.22	039.07
(b) Financial Assets (i) Trade Receivables	492.12	584.36
(ii) Cash and Cash Equivalents	212.69	235.31
(iii) Other Financial Assets	4.31	3.99
(iv) Loans	179.99	0.97
(c) Current Tax Assets	-	0.57
(c) Other Current Assets	103.72	128.81
(C) Other Current Assets	1,615.06	1,593.10
Total Assets	4,110.49	3,866.03
	,	-,
II. EQUITY AND LIABILITIES		
(1) Equity	05.07	05.07
(a) Share capital	85.07	85.07
(b) Other equity	2,198.01	1,925.65
Equity Attributable to Owners	2,283.08	2,010.72
Non Controlling Interest	76.50	54.21
(2) Liabilities	2,359.58	2,064.93
(a) Non-current liabilities		
(i) Financial Liabilities		
-Borrowings	828.42	764.76
-Other Financial Liabilities	54.87	53.58
-Lease Liabilities	JT.07	-
(ii) Deferred Tax Liabilities (Net)	72.76	88.17
(iii) Other non-current liabilities	181.20	59.93
(iii) Other from current habilities	101.20	33.33
(h) Comant linkilitin	1,137.25	966.44
(b) Current liabilities		
(i) Financial Liabilities	22.70	225 42
-Borrowings -Trado Payablos	32.79	325.42
-Trade Payables -Other Financial Liabilities	280.86 198.87	200.23 136.17
-Other Financial Liabilities -Lease Liabilties	130.07	130.1/
(ii) Other Current Liabilities	26.36	168.26
(iii) Current Tax Liabilities (Net)	30.83	100.20
(iii) Provisions	43.95	4.56
(III) I TOVISIONS	613.66	<b>834.66</b>
	1,750.91	1,801.10
Total Equity and Liabilities	4,110.49	3,866.03
	.,,	5,000.05



Hester Biosciences Limited Head Office Pushpak, 1st Floor

Panchvati Circle Motilal Hirabhai Road Ahmedabad 380006 Gujarat, India

Phone +9179 26445106

Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +9179 26445105

Email mail@hester.in Toll Free 1800 233 7937

www.hester.in

CIN L99999GJ1987PLC022333

### STATEMENT OF AUDITED CONSOLIDATED CASH FLOWS FOR THE YEAR ENDED ON 31 MARCH 2021

	Am	ount in INR Million
	Year E	nded
Particulars	31-03-2021	31-03-2020
	Audited	Audited
A. Cash Flow from Operating Activities		
Profit Before Tax	501.03	413.26
Adjustments For:		
Depreciation and Amortisation Expense	133.14	132.30
Exceptional Items	33.21	-
Loss on diposal of investment in subsidiary	-	0.74
Provision for doubtful debt	2.87	-
Bad Debts Written off	6.90	0.62
(Profit) / Loss on Sale of Property, Plant & Equipments	23.22	(5.31)
Interest expense	40.25	76.66
Interest Income	(12.94)	(3.73)
Operating Profit / (Loss) Before Changes in Working Capital	727.67	614.54
Adjustments For:		
Trade Receivables	82.47	(256.33)
Inventories	17.46	(131.82)
Other Assets	25.09	-
Other Non Current Assets	16.90	33.29
Trade Payables	80.63	98.63
Other Current Liabilities	(108.88)	96.07
Short-term Provisions	(4.10)	(3.33)
Loans	(179.03)	1.61
Other Financial Liability	63.98	29.60
Other Financial Assets	(2.42)	(5.18)
Cash Generated From Operations	719.75	477.09
Income Tax paid (net)	(139.36)	(109.36)
Net Cash Flow from Operating Activities (A)	580.39	367.73
B. Cash Flow from Investing Activities		
Proceeds from sale of Property, Plant & Equipment	0.42	9.81
Capital Expenditure on Property, Plant & Equipment	(407.42)	(734.98)
Interest received	12.67	3.73
Investment in Bank Deposits (net)	10.74	(23.30)
Net Cash Flow from / (used in) Investing Activities (B)	(383.58)	(744.73)



Phone +9179 26445106

Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +9179 26445105 Email mail@hester.in
Toll Free 1800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

	Year E	nded
Particulars	31-03-2021	31-03-2020
	Audited	Audited
C. Cash Flow from Financing Activities		
Proceeds from long term borrowings	63.67	181.25
Proceeds from Issue of Share Capital in subsidiary entities from Non-	19.64	-
controlling interest shareholers		
Proceeds/(Repayment) of Short-term Borrowings (net)	(292.64)	100.44
Interest Paid	(40.25)	(76.66)
Proceeds from Grants	123.54	54.19
Dividend Paid (Including Dividend Distribution Tax)	(56.15)	(71.79)
Net Cash Flow from / (used in) Financing Activities (C)	(182.19)	187.43
Exchange rate fluctuation arising on consolidation (D)	(37.24)	18.42
Net Increase / (Decrease) in Cash and Cash Equivalents	(22.62)	(171.16)
(A+B+C+D)		
Cash and Cash Equivalents at the beginning of the year	235.31	406.47
Cash and Cash Equivalents at the end of the year	212.69	235.31



Phone +9179 26445106

Plant Address Village Merda-Ardraj Taluka Kadi District Mehsana Gujarat 382721, India Phone +9179 26445105

Email mail@hester.in Toll Free 1800 233 7937

www.hester.in

CIN L99999GJ1987PLC022333

#### Notes:

- 1. The above consolidated financial results of Hester Biosciences Limited (the "Company") and its subsidiaries (together referred as the "Group") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company in their respective meetings held on 8 June 2021.
- 2. Exceptional items includes loss on disposal of Patan farm aggregating to INR 33.21 million.
- 3. Followings are the details of segment wise revenue, results, segment assets and liabilities:

(Amount in TNR Million)

(Amount in INR Milli						
	Q	uarter Ende	ed	Year E	inded	
Particulars	31-03- 2021	31-12- 2020	31-03- 2020	31-03- 2021	31-03- 2020	
Segment Revenue						
a. Pou try Healthcare	527.00	395.83	302.22	1,564.51	1,203.46	
b. Ani I Healthcare	114.75	173.11	133.99	578.81	629.22	
Total	641.75	568.94	436.20	2,143.32	1,832.67	
Segment Results						
a. Poultry Healthcare	168.48	101.03	59.92	389.11	309.40	
b. Animal Healthcare	-12.51	90.80	61.81	180.92	126.03	
Total	155.97	191.83	121.73	570.03	435.43	
Finance Costs	14.35	15.23	33.05	66.04	81.34	
Other unallocated expenditure/ (income) (net)	2.96	-	26.27	2.96	-59.17	
Profit before Tax	138.66	176.60	62.41	501.03	413.26	
Segment Assets						
a. Poultry Healthcare	1,891.35	1,925.30	2,117.64	1,891.35	2,117.64	
b. Animal Healthcare	1,993.65	2,360.74	1,618.50	1,993.65	1,618.50	
Unallocated Assets	225.49	659.10	129.89	225.49	129.89	
Total	4,110.49	4,945.14	3,866.03	4,110.49	3,866.03	
Segment Liabilities						
a. Poultry Healthcare	220.23	240.19	154.73	220.23	154.73	
b. Animall Healthcare	309.87	660.36	321.36	309.87	321.36	
Unallocated Liabilities	1,220.81	1,323.08	1,325.01	1,220.81	1,325.01	
Total	1,750.91	2,223.63	1,801.10	1,750.91	1,801.10	

- 4. The Board of Directors has recommended a dividend of INR 10 per equity share (100%) for FY21, subject to the approval of the shareholders in the ensuing Annual General Meeting.
- 5. The Code on Social Security, 2020 ("Code") relating to employees benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/ interpretation have not yet been issued. The Group will assess the impact of the Code when it comes into effect and will record any related impact in the period the Code becomes effective.



Phone +9179 26445106

Plant Address
Village Merda-Ardraj
Taluka Kadi
District Mehsana
Gujarat 382721, India
Phone +9179 26445105

Email mail@hester.in
Toll Free 1800 233 7937
www.hester.in

CIN L99999GJ1987PLC022333

6. The figures for the last quarters are the balancing figures between the audited figures in respect of the full year ending 31 March 2021 and 31 March2020 and the unaudited published year-to-date figures up to 31 December 2020 and 31 December 2019 respectively, being the date of the end of the third quarter of the respective financial years which were subjected to limited review.

- 7. The figures for the previous year/periods have been regrouped/reclassified wherever necessary to make them comparable to current year/period.
- 8. Key numbers of the standalone financial results of the Company for the quarter and year ended on 31 March 2021 are as under:

Amount in INR Million

Amount in this million							
	Qua	arter Ende	ed	Year Ended			
Particulars	31-03- 2021	31-12- 2020	31-03- 2020	31-03- 2021	31-03- 2020		
Total Income	632.78	534.53	417.29	2,101.25	1,723.52		
Profit Before Tax and Exceptional Items	178.17	178.45	65.01	600.60	412.29		
Profit before tax	125.40	178.45	65.01	547.83	412.29		
Profit After Tax	88.59	132.91	50.03	399.01	312.24		
Total Comprehensive Income for the period	88.60	133.62	50.37	401.15	308.23		

The Standalone Financial Results are available at the Company's website <u>hester.in</u> and on the website of the stock exchanges <u>www.bseindia.com</u> and <u>www.nseindia.com</u>.

For and on behalf of the Board of Directors

Place: Ahmedabad

Date: 08.06.2021 CEO & Managing Director

DIN: 00438037

Rajiv Gandhi

## Chandulal M. Shah & Co.

## **CHARTERED ACCOUNTANTS**

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.

Tel.: 079-2960 1085 • (M) 90330 34430 • E-mail: cmshah@cmshah.com • Website: www.cmshah.com

Independent Auditor's Report on Quarterly and Year to date Audited Consolidated financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To The Board of Directors of Hester Biosciences Limited

### **Opinion**

We have audited the accompanying statement of consolidated financial results of **Hester Biosciences Limited** ("the Holding company") and its subsidiaries (the Holding and its subsidiaries together referred to as "the Group") for the quarter and year ended 31st March, 2021 ("the Statement"), attached herewith, being submitted by the Holding company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of report of other auditors on separate audited financial statements/financial results/financial information of subsidiaries, the Statement:

i. includes the results of the following subsidiaries:

## Sr. No. Name of the Company

- 1 Texas Lifesciences Private Limited
- 2 Hester Biosciences Nepal Private Limited
- 3 Hester Biosciences Africa Limited
- 4 Hester Biosciences Kenya Limited
- 5 Hester Biosciences Tanzania Limited (Stepdown subsidiary)
- ii. is presented in accordance with the requirements of Regulation 33 of Listing Regulations in this regard; and
- iii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of the consolidated net profit and other comprehensive income and other financial information for the quarter and year ended March 31, 2021.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013, as amended ('the Act'). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained by us and other auditors in terms of their reports referred to in "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our audit opinion.



### Management's Responsibilities for the Consolidated Financial Results

The Statement have been prepared on the basis of the consolidated financial statements. The Holding Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net consolidated profit and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the Companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the Companies included in the Group are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies included in the Group are also responsible for overseeing the Group's financial reporting process.

#### Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

e e las regis Africa da vide d'ale d'

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud
  or error, design and perform audit procedures responsive to those risks, and obtain audit
  evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not
  detecting a material misstatement resulting from fraud is higher than for one resulting from
  error, as fraud may involve collusion, forgery, intentional omissions; misrepresentations, or
  the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to design
  audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act,
  we are also responsible for expressing our opinion on whether the company has adequate
  internal financial controls with reference to financial statements in place and the operating
  effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the
  disclosures, and whether the Statement represent the underlying transactions and events in a
  manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial results/financial
  information of the Group of which we are the independent auditors to express an opinion on
  the Statement. We are responsible for the direction, supervision and performance of the audit
  of financial information of such entities included in the consolidated financial results of which
  we are the independent auditors. For the other entities included in the consolidated financial
  results, which have been audited by other auditors, such other auditors remain responsible for
  the direction, supervision and performance of the audits carried out by them. We remain solely
  responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, as amended, to the extent applicable.

#### Other Matter

a. The accompanying Statement includes the audited financial results/statements and other financial information, in respect of the 4 subsidiaries and 1 stepdown subsidiary, whose financial statements/results reflect total assets of Rs. 1923.33 Mn as at 31st March, 2021 and total revenue of Rs. 103.95 Mn and Rs. 310.72 Mn, total net profit/(loss) after tax of Rs. 2.5 Mn and Rs. (34.27) Mn and total comprehensive income/(loss) of Rs. 3.56 Mn and Rs. (32.60) Mn for the quarter and the year ended on that date respectively, and net cash inflows of Rs. 16.83 Mn for the year ended 31st March, 2021, as considered in the Statement which have been audited by their respective independent auditors.

The independent auditors' reports on the financial statements/financial results/financial information of the above referred entities have been furnished to us by the Management and our opinion on the Statement in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of such auditors and the procedures performed by us as stated in paragraph above.

Our opinion on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditors.



# Chandulal M. Shah & Co. CHARTERED ACCOUNTANTS

- b. The financial results include the results for the quarter ended March 31, 2021 being the balancing figures between the audited figures with respect to full financial year ended March 31, 2021 and the published unaudited year-to-date figures upto the end of the third quarter of the current financial year, which were subject to limited review by us, as required under the Listing Regulations.
- c. The comparative financial information of the Company for the corresponding quarter and year ended March 31, 2020, included in these standalone financial results, were audited by the predecessor auditor who expressed an unmodified opinion on those financial information on 26<sup>th</sup> June, 2020.

For, Chandulal M. Shah & Co.

Chartered Accountants FRN 101698W

. ...

Arpit D. Shah Partner

M. No. 135188

UDIN: 21135188AAAACQ5718

a taga da santa

AHMEDADAD \*

Date: 8th June 2021

Place: Ahmedabad

# Chandulal M. Shah & Co.

## **CHARTERED ACCOUNTANTS**

A/6, 6th Floor, Wing-A, Safal Profitaire, Opp. Prahladnagar Garden, Corporate Road, Prahladnagar, Ahmedabad-380015.

Tel.: 079-2960 1085 • (M) 90330 34430 • E-mail: cmshah@cmshah.com • Website: www.cmshah.com

Independent Auditor's Report on Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
Hester Biosciences Limited

#### **Opinion**

We have audited the accompanying standalone financial results of **Hester Biosciences Limited** ('the Company') for the quarter and year ended March 31, 2021 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').

In our opinion and to the best of our information and according to the explanations given to us, the Statement:

a. is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations in this regard; and

b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2021.

### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Companies Act, 2013, as amended ('the Act'). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

## Management's Responsibilities for the Standalone Financial Results

The Statement has been prepared on the basis of the standalone financial statements. The Company's Board of Directors are responsible for the preparation and presentation of the Statement that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes



maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

## Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to
  fraud or error, design and perform audit procedures responsive to those risks, and obtain
  audit evidence that is sufficient and appropriate to provide a basis for our opinion. The
  risk of not detecting a material misstatement resulting from fraud is higher than for one
  resulting from error, as fraud may involve collusion, forgery, intentional omissions;
  misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial control relevant to the audit in order to
  design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i)
  of the Act, we are also responsible for expressing our opinion on whether the company
  has adequate internal financial controls with reference to financial statements in place and
  the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis
  of accounting and, based on the audit evidence obtained, whether a material uncertainty
  exists related to events or conditions that may cast significant doubt on the Company's



ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

 Evaluate the overall presentation, structure and content of the standalone financial results, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matter

- The Statement includes the results for the quarter ended March 31, 2021 being the balancing
  figures between the audited figures with respect to full financial year ended March 31, 2021
  and the published unaudited year-to-date figures upto the third quarter of the current financial
  year, which were subjected to limited review by us, as required under the Listing Regulations.
- 2. The comparative financial information of the Company for the corresponding quarter and year ended March 31, 2020, included in these standalone financial results, were audited by the predecessor auditor who expressed an unmodified opinion on those financial information on 26th June, 2020.

For, Chandulal M. Shah & Co.

Chartered Accountants FRN 101698W

Date: 8th June 2021

Place: Ahmedabad

AHMEDABAD \*

CHARTERED ACCOUNTAINS

Arpit D. Shah

Partner

M. No. 135188

UDIN: 21135188AAAACP7004